Update shared on09 Sep 2025
Fair value Increased 5.47%Driven by an improved net profit margin and a modest reduction in future P/E, analysts have raised UroGen Pharma’s consensus price target from $32.00 to $33.75.
What's in the News
- ZUSDURI (mitomycin) received FDA approval as the first and only approved therapy for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), with U.S. availability expected on or around July 1, 2025.
- Phase 3 ENVISION trial data showed a 24-month duration of response of 72.2% among patients achieving complete response at three months, supporting ZUSDURI’s sustained efficacy.
- Results from a five-year extension of the Phase 2b OPTIMA II trial demonstrated durable, long-term complete responses in patients treated with ZUSDURI.
- A Phase 3b study indicated that ZUSDURI can be safely and effectively administered by trained health professionals in a home setting.
- Patient enrollment was completed in the Phase 3 UTOPIA trial for UGN-103, a next-generation mitomycin product designed to improve upon ZUSDURI, featuring a shorter manufacturing process and simplified preparation.
Valuation Changes
Summary of Valuation Changes for UroGen Pharma
- The Consensus Analyst Price Target has risen from $32.00 to $33.75.
- The Net Profit Margin for UroGen Pharma has risen from 29.57% to 32.52%.
- The Future P/E for UroGen Pharma has fallen slightly from 15.96x to 15.34x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.